Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (The MET-REMODEL Study): Rationale and design of the MET-REMODEL study

Mohapradeep Mohan, Stephen McSwiggan, Fatima Baig, Lynn Rutherford, Chim C. Lang (Lead / Corresponding author)

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Left ventricular hypertrophy (LVH) is a common and independent risk factor for cardiovascular events in patients with coronary artery disease (CAD). Controlling blood pressure is the standard approach to the management of LVH, but this is only partially effective as LVH also persists in normotensive patients. Apart from blood pressure (BP), other main risk factors associated with LVH are insulin resistance (IR) and central obesity. The diabetic medication, Metformin, reduces IR and aids weight loss and may therefore regress LVH. The MET REMODEL study will investigate the ability of Metformin to regress LVH in 64 patients with CAD. The MET-REMODEL trial is a single-center, phase IV, double blind, randomized, placebo-controlled trial to investigate the efficacy of Metformin in regression of the independent cardiac risk factor of LVH in patients with CAD who are insulin resistant. A minimum of 64 adults with a history of CAD with LVH and IR will be randomized into two groups to receive, either Metformin XL or placebo. The primary endpoint of this trial is to investigate any change in left ventricular mass index. Secondary endpoints include changes to insulin resistance measured using fasting insulin resistance index (FIRI), obesity, LV size, and function and improvement in endothelial function. A positive result will assist clinicians to identify a new mechanism for LVH regression by administering Metformin XL. This may also lead to investigating the mortality benefit of Metformin in patients with CAD and LVH.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalCardiovascular Therapeutics
Volume33
Issue number1
Early online date27 Dec 2014
DOIs
Publication statusPublished - 1 Feb 2015

Fingerprint

Metformin
Left Ventricular Hypertrophy
Coronary Disease
Insulin Resistance
Coronary Artery Disease
Placebos
Blood Pressure
Aptitude
Abdominal Obesity
Weight Loss
Fasting
Randomized Controlled Trials
Obesity
Insulin
Mortality

Keywords

  • Coronary artery disease
  • Insulin resistance
  • Left ventricular hypertrophy

Cite this

@article{9cab95dbf87e45f5852718558e977e28,
title = "Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (The MET-REMODEL Study): Rationale and design of the MET-REMODEL study",
abstract = "Left ventricular hypertrophy (LVH) is a common and independent risk factor for cardiovascular events in patients with coronary artery disease (CAD). Controlling blood pressure is the standard approach to the management of LVH, but this is only partially effective as LVH also persists in normotensive patients. Apart from blood pressure (BP), other main risk factors associated with LVH are insulin resistance (IR) and central obesity. The diabetic medication, Metformin, reduces IR and aids weight loss and may therefore regress LVH. The MET REMODEL study will investigate the ability of Metformin to regress LVH in 64 patients with CAD. The MET-REMODEL trial is a single-center, phase IV, double blind, randomized, placebo-controlled trial to investigate the efficacy of Metformin in regression of the independent cardiac risk factor of LVH in patients with CAD who are insulin resistant. A minimum of 64 adults with a history of CAD with LVH and IR will be randomized into two groups to receive, either Metformin XL or placebo. The primary endpoint of this trial is to investigate any change in left ventricular mass index. Secondary endpoints include changes to insulin resistance measured using fasting insulin resistance index (FIRI), obesity, LV size, and function and improvement in endothelial function. A positive result will assist clinicians to identify a new mechanism for LVH regression by administering Metformin XL. This may also lead to investigating the mortality benefit of Metformin in patients with CAD and LVH.",
keywords = "Coronary artery disease, Insulin resistance, Left ventricular hypertrophy",
author = "Mohapradeep Mohan and Stephen McSwiggan and Fatima Baig and Lynn Rutherford and Lang, {Chim C.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1111/1755-5922.12101",
language = "English",
volume = "33",
pages = "1--8",
journal = "Cardiovascular Therapeutics",
issn = "1755-5914",
publisher = "Wiley",
number = "1",

}

TY - JOUR

T1 - Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (The MET-REMODEL Study)

T2 - Rationale and design of the MET-REMODEL study

AU - Mohan, Mohapradeep

AU - McSwiggan, Stephen

AU - Baig, Fatima

AU - Rutherford, Lynn

AU - Lang, Chim C.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Left ventricular hypertrophy (LVH) is a common and independent risk factor for cardiovascular events in patients with coronary artery disease (CAD). Controlling blood pressure is the standard approach to the management of LVH, but this is only partially effective as LVH also persists in normotensive patients. Apart from blood pressure (BP), other main risk factors associated with LVH are insulin resistance (IR) and central obesity. The diabetic medication, Metformin, reduces IR and aids weight loss and may therefore regress LVH. The MET REMODEL study will investigate the ability of Metformin to regress LVH in 64 patients with CAD. The MET-REMODEL trial is a single-center, phase IV, double blind, randomized, placebo-controlled trial to investigate the efficacy of Metformin in regression of the independent cardiac risk factor of LVH in patients with CAD who are insulin resistant. A minimum of 64 adults with a history of CAD with LVH and IR will be randomized into two groups to receive, either Metformin XL or placebo. The primary endpoint of this trial is to investigate any change in left ventricular mass index. Secondary endpoints include changes to insulin resistance measured using fasting insulin resistance index (FIRI), obesity, LV size, and function and improvement in endothelial function. A positive result will assist clinicians to identify a new mechanism for LVH regression by administering Metformin XL. This may also lead to investigating the mortality benefit of Metformin in patients with CAD and LVH.

AB - Left ventricular hypertrophy (LVH) is a common and independent risk factor for cardiovascular events in patients with coronary artery disease (CAD). Controlling blood pressure is the standard approach to the management of LVH, but this is only partially effective as LVH also persists in normotensive patients. Apart from blood pressure (BP), other main risk factors associated with LVH are insulin resistance (IR) and central obesity. The diabetic medication, Metformin, reduces IR and aids weight loss and may therefore regress LVH. The MET REMODEL study will investigate the ability of Metformin to regress LVH in 64 patients with CAD. The MET-REMODEL trial is a single-center, phase IV, double blind, randomized, placebo-controlled trial to investigate the efficacy of Metformin in regression of the independent cardiac risk factor of LVH in patients with CAD who are insulin resistant. A minimum of 64 adults with a history of CAD with LVH and IR will be randomized into two groups to receive, either Metformin XL or placebo. The primary endpoint of this trial is to investigate any change in left ventricular mass index. Secondary endpoints include changes to insulin resistance measured using fasting insulin resistance index (FIRI), obesity, LV size, and function and improvement in endothelial function. A positive result will assist clinicians to identify a new mechanism for LVH regression by administering Metformin XL. This may also lead to investigating the mortality benefit of Metformin in patients with CAD and LVH.

KW - Coronary artery disease

KW - Insulin resistance

KW - Left ventricular hypertrophy

UR - http://www.scopus.com/inward/record.url?scp=84921467826&partnerID=8YFLogxK

U2 - 10.1111/1755-5922.12101

DO - 10.1111/1755-5922.12101

M3 - Review article

C2 - 25545400

AN - SCOPUS:84921467826

VL - 33

SP - 1

EP - 8

JO - Cardiovascular Therapeutics

JF - Cardiovascular Therapeutics

SN - 1755-5914

IS - 1

ER -